Non-viral delivery of the connexin 43 gene with histone deacetylase inhibitor to human nasopharyngeal tumor cells enhances gene expression and inhibits in vivo tumor growth

International Journal of Oncology

Volumn 30, Issue 6, 2007, Pages 1427-1439

  Hattori, Yoshiyuki ^a   Fukushima, Masayoshi ^a   Maitani, Yoshie ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

4 phenylbutyrate; Apoptosis; Connexin 43; Folate linked nanoparticle; Gap junction; Gene therapy; Histone deacetylase inhibitor; Nasopharyngeal cancer; Transfection

Indexed keywords

4 PHENYLBUTYRIC ACID; 4-PHENYLBUTYRIC ACID; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; CASPASE 3; CASPASE 7; CONNEXIN 43; ENZYME INHIBITOR; HISTONE DEACETYLASE; MESSENGER RNA; NANOPARTICLE; PROTEIN BCL 2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONFOCAL MICROSCOPY; DNA MICROARRAY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; METHODOLOGY; NASOPHARYNX TUMOR; PHYSIOLOGY; PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CASPASE 7; CELL PROLIFERATION; CONNEXIN 43; ENZYME INHIBITORS; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; HISTONE DEACETYLASES; HUMANS; MICROSCOPY, CONFOCAL; NANOPARTICLES; NASOPHARYNGEAL NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENYLBUTYRATES; PLASMIDS; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34447288748     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.6.1427     Document Type: Article

References (47)

1. Vine AL and Bertram JS: Cancer chemoprevention by connexins. Cancer Metastasis Rev 21: 199-216, 2002.
2. Yamasaki H and Naus CC: Role of connexin genes in growth control. Carcinogenesis 17: 1199-1213, 1996.
3. Lee SW, Tomasetto C, Paul D, Keyomarsi K and Sager R: Transcriptional downregulation of gap-junction proteins blocks junctional communication in human mammary tumor cell lines. J Cell Biol 118: 1213-1221, 1992.
4. Tomasetto C, Neveu MJ, Daley J, Horan PK and Sager R: Specificity of gap junction communication among human mammary cells and connexin transfectants in culture. J Cell Biol 122: 157-167, 1993.
5. Habermann H, Ray V, Habermann W and Prins GS: Alterations in gap junction protein expression in human benign prostatic hyperplasia and prostate cancer. J Urol 167: 655-660, 2002.
6. Huang RP, Hossain MZ, Sehgal A and Boynton AL: Reduced connexin43 expression in high-grade human brain glioma cells. J Surg Oncol 70: 21-24, 1999. (Pubitemid 29061990)
7. Sawey MJ, Goldschmidt MH, Risek B, Gilula NB and Lo CW: Perturbation in connexin 43 and connexin 26 gap-junction expression in mouse skin hyperplasia and neoplasia. Mol Carcinog 17: 49-61, 1996.
8. Zhang ZQ, Zhang W, Wang NQ, Bani-Yaghoub M, Lin ZX and Naus CC: Suppression of tumorigenicity of human lung carcinoma cells after transfection with connexin43. Carcinogenesis 19: 1889-1894, 1998.
9. Oyamada Y, Oyamada M, Fusco A and Yamasaki H: Aberrant expression, function and localization of connexins in human esophageal carcinoma cell lines with different degrees of tumorigenicity. J Cancer Res Clin Oncol 120: 445-453, 1994.
10. Pelin K, Hirvonen A and Linnainmaa K: Expression of cell adhesion molecules and connexins in gap junctional intercellular communication deficient human mesothelioma tumour cell lines and communication competent primary mesothelial cells. Carcinogenesis 15: 2673-2675, 1994. (Pubitemid 24343711)
11. Mehta PP, Perez-Stable C, Nadji M, Mian M, Asotra K and Roos BA: Suppression of human prostate cancer cell growth by forced expression of connexin genes. Dev Genet 24: 91-110, 1999.
12. Zhang YW, Kaneda M and Morita I: The gap junction-independent tumor-suppressing effect of connexin 43. J Biol Chem 278: 44852-44856, 2003.
13. Nicholas TW, Read SB, Burrows FJ and Kruse CA: Suicide gene therapy with Herpes simplex virus thymidine kinase and ganciclovir is enhanced with connexins to improve gap junctions and bystander effects. Histol Histopathol 18: 495-507, 2003.
14. Huang RP, Hossain MZ, Huang R, Gano J, Fan Y and Boynton AL: Connexin 43 (cx43) enhances chemotherapy-induced apoptosis in human glioblastoma cells. Int J Cancer 92: 130-138, 2001. (Pubitemid 32187042)
15. Tanaka M and Grossman HB: Connexin 26 induces growth suppression, apoptosis and increased efficacy of doxorubicin in prostate cancer cells. Oncol Rep 11: 537-541, 2004.
16. Tanaka M and Grossman HB: Connexin 26 gene therapy of human bladder cancer: induction of growth suppression, apoptosis, and synergy with Cisplatin. Hum Gene Ther 12: 2225-2236, 2001. (Pubitemid 34075186)
17. Peart MJ, Tainton KM, Ruefli AA, et al: Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 63: 4460-4471, 2003.
18. Blagosklonny MV, Robey R, Sackett DL, et al: Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther 1: 937-941, 2002.
19. Ishiguro K and Sartorelli AC: Activation of transiently transfected reporter genes in 3T3 Swiss cells by the inducers of differentiation/apoptosis- dimethylsulfoxide, hexamethylene bisacetamide and trichostatin A. Eur J Biochem 271: 2379-2390, 2004.
20. Piekarz R and Bates S: A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des 10: 2289-2298, 2004.
21. Yamano T, Ura K, Morishita R, Nakajima H, Monden M and Kaneda Y: Amplification of transgene expression in vitro and in vivo using a novel inhibitor of histone deacetylase. Mol Ther 1: 574-580, 2000.
22. Imanishi R, Ohtsuru A, Iwamatsu M, et al: A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy. J Clin Endocrinol Metab 87: 4821-4824, 2002. (Pubitemid 35247082)
23. Takimoto R, Kato J, Terui T, et al: Augmentation of antitumor effects of p53 gene therapy by combination with HDAC inhibitor. Cancer Biol Ther 4: 421-428, 2005.
24. Yamamoto S, Yamano T, Tanaka M, et al: A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma. Cancer Gene Ther 10: 179-186, 2003.
25. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS and Leamon CP: Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 338: 284-293, 2005. (Pubitemid 40312593)
26. Hattori Y and Maitani Y: Folate-linked lipid-based nanoparticle for targeted gene delivery. Curr Drug Delivery 2: 243-252, 2005.
27. Hattori Y, Kubo H, Higashiyama K and Maitani Y: Folate-linked nanoparticles formed with DNA complexes in sodium chloride solution enhance transfection efficiency. J Biomed Nanotech 1: 176-184, 2005.
28. Hattori Y and Maitani Y: Folate-linked nanoparticle-mediated suicide gene therapy in human prostate cancer and nasopharyngeal cancer with herpes simplex virus thymidine kinase. Cancer Gene Ther 12: 796-809, 2005.
29. Robe PA, Jolois O, N'Guyen M, et al: Modulation of the HSV-TK/ganciclovir bystander effect by n-butyrate in glioblastoma: correlation with gap-junction intercellular communication. Int J Oncol 25: 187-192, 2004.
30. Hattori Y and Maitani Y: Enhanced in vitro DNA transfection efficiency by novel folate-linked nanoparticles in human prostate cancer and oral cancer. J Control Release 97: 173-183, 2004.
31. Bartova E, Pachernik J, Harnicarova A, et al: Nuclear levels and patterns of histone H3 modification and HP1 proteins after inhibition of histone deacetylases. J Cell Sci 118: 5035-5046, 2005.
32. Govindarajan R, Zhao S, Song XH, et al: Impaired trafficking of connexins in androgen-independent human prostate cancer cell lines and its mitigation by alpha-catenin. J Biol Chem 277: 50087-50097, 2002. (Pubitemid 36014462)
33. Jiang JX and Gu S: Gap junction- and hemichannel-independent actions of connexins. Biochim Biophys Acta 1711: 208-214, 2005.
34. Zhang YW, Nakayama K, Nakayama K and Morita I: A novel route for connexin 43 to inhibit cell proliferation: negative regulation of S-phase kinase-associated protein (Skp 2). Cancer Res 63: 1623-1630, 2003.
35. Lee JH and Paull TT: ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science 308: 551-554, 2005. (Pubitemid 40570585)
36. Shapiro GI, Edwards CD and Rollins BJ: The physiology of p16(INK4A)-mediated G1 proliferative arrest. Cell Biochem Biophys 33: 189-197, 2000.
37. Desai-Mehta A, Cerosaletti KM and Concannon P: Distinct functional domains of nibrin mediate Mre11 binding, focus formation, and nuclear localization. Mol Cell Biol 21: 2184-2191, 2001.
38. Gatei M, Young D, Cerosaletti KM, et al: ATM-dependent phosphorylation of nibrin in response to radiation exposure. Nat Genet 25: 115-119, 2000.
39. Seul KH, Kang KY, Lee KS, Kim SH and Beyer EC: Adenoviral delivery of human connexin37 induces endothelial cell death through apoptosis. Biochem Biophys Res Commun 319: 1144-1151, 2004.
40. Asklund T, Appelskog IB, Ammerpohl O, Ekstrom TJ and Almqvist PM: Histone deacetylase inhibitor 4-phenylbutyrate modulates glial fibrillary acidic protein and connexin 43 expression, and enhances gap-junction communication, in human glioblastoma cells. Eur J Cancer 40: 1073-1081, 2004. (Pubitemid 38496266)
41. Ammerpohl O, Thormeyer D, Khan Z, et al: HDACi phenylbutyrate increases bystander killing of HSV-tk transfected glioma cells. Biochem Biophys Res Commun 324: 8-14, 2004.
42. Fukushima M, Hattori Y, Yoshizawa T and Maitani Y: Combination of non-viral connexin 43 gene therapy and docetaxel inhibits the growth of human prostate cancer in mice. Int J Oncol 30: 225-231, 2007.
43. Chow LS, Wang X, Kwong DL, Sham JS, Tsao SW and Nicholls JM: Effect of p16INK4a on chemosensitivity in nasopharyngeal carcinoma cells. Int J Oncol 17: 135-140, 2000.
44. Pili R, Kruszewski MP, Hager BW, Lantz J and Carducci MA: Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res 61: 1477-1485, 2001. (Pubitemid 34292576)
45. Williams RJ: Trichostatin A, an inhibitor of histone deacetylase, inhibits hypoxia-induced angiogenesis. Expert Opin Investig Drugs 10: 1571-1573, 2001.
46. Kim MS, Kwon HJ, Lee YM, et al: Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7: 437-443, 2001.
47. Galaup A, Opolon P, Bouquet C, et al: Combined effects of docetaxel and angiostatin gene therapy in prostate tumor model. Mol Ther 7: 731-740, 2003.